Laura Brege currently serves as a consultant to life sciences companies. From 2012 to 2015, she served as the President and Chief Executive Officer of Nodality, Inc. Prior to this position, she served as Executive Vice President, Corporate Affairs, for Onyx Pharmaceuticals. In this role, Ms. Brege was responsible for the oversight of all external relationships, including medical and scientific affairs, government affairs and public affairs. Previously, Ms. Brege held the roles of Chief Operating Officer, Executive Vice President and Chief Business Officer for Onyx. In these roles, she oversaw the expansion of key corporate capabilities and strengthened the company’s financial position by significantly adding to its cash reserves. Prior to joining Onyx in 2006, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm, and Senior Vice President and Chief Financial Officer at COR Therapeutics. Ms. Brege currently serves as a Director of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD), Aratana Therapeutics, Inc. (NASDAQ: PETX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago. Laura Brege currently serves as a consultant to life sciences companies. From 2012 to 2015, she served as the President and Chief Executive Officer of Nodality, Inc. Prior to this position, she served as Executive Vice President, Corporate Affairs, for Onyx Pharmaceuticals. In this role, Ms. Brege was responsible for the oversight of all external relationships, including medical and scientific affairs, government affairs and public affairs. Previously, Ms. Brege held the roles of Chief Operating Officer, Executive Vice President and Chief Business Officer for Onyx. In these roles, she oversaw the expansion of key corporate capabilities and strengthened the company’s financial position by significantly adding to its cash reserves. Prior to joining Onyx in 2006, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm, and Senior Vice President and Chief Financial Officer at COR Therapeutics. Ms. Brege currently serves as a Director of Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD), Aratana Therapeutics, Inc. (NASDAQ: PETX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago.

Oncology